Patricia Maria Lucia Adriana van Den Bemt

Patricia Maria Lucia Adriana van Den Bemt

Auto-generated profile, based on publicly available information

Patricia Maria Lucia Adriana van Den Bemt

Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2000 in Drug Safety
Verified
Journal Article
Closed access
PDF file
PBPatricia M.L.A. van Den Bemt
Patricia M.L.A. van Den Bemt
TEToine C.G. Egberts
Toine C.G. Egberts
LBLolkje T.W. de Jong-Van Den Berg
Lolkje T.W. de Jong-Van Den Berg
JBJacobus R.B.J. Brouwers
Jacobus R.B.J. Brouwers

1 May 2010 in European journal of pain
Verified
Journal Article
Closed access
MBMaren I. Blonk
Maren I. Blonk
BKBrigitte G. Koder
Brigitte G. Koder
PBPatricia M.L.A. van Den Bemt
Patricia M.L.A. van Den Bemt
FHFrank J.P.M. Huygen
Frank J.P.M. Huygen

1 April 2002 in Critical Care Medicine
Verified
Journal Article
Closed access
PBPatricia M. L. A. van Den Bemt
Patricia M. L. A. van Den Bemt
RFRoel Fijn
Roel Fijn
PVPeter H. J. van der Voort
Peter H. J. van der Voort
AGAnnet A. Gossen
Annet A. Gossen
TEToine C. G. Egberts
Toine C. G. Egberts
JBJacobus R. B. J. Brouwers
Jacobus R. B. J. Brouwers
The study aimed to identify both the frequency and the determinants of drug administration errors in the intensive care unit. Administration errors were detected by using the disguised-observation technique (observation of medication administrations by nurses, without revealing the aim of this observation to the nurses). Two Dutch hospitals. The drug administrations to patients in the intensive care units of two Dutch hospitals were observed during five consecutive days. None. A total of 233 medications for 24 patients were observed to be administered (whether ordered or not) or were observed to be omitted. When wrong time errors were included, 104 administrations with at least one error were observed (frequency, 44.6%), and when they were excluded, 77 administrations with at least one error were observed (frequency, 33.0%). When we included wrong time errors, day of the week (Monday, odds ratio [OR] 2.69, confidence interval [CI] 1.42–5.10), time of day (6–10 pm, OR 0.28, CI 0.10–0.78), and drug class (gastrointestinal, OR 2.94, CI 1.48–5.85; blood, OR 0.12, CI 0.03–0.54; and cardiovascular, OR 0.38, CI, 0.16–0.90) were associated with the occurrence of errors. When we excluded wrong time errors, day of the week (Monday, OR 3.14, CI 1.66–5.94), drug class (gastrointestinal, OR 3.47, CI 1.76–6.82; blood, OR 0.21, CI 0.05–0.91; and respiratory, OR 0.22, CI 0.08–0.60), and route of administration (oral by gastric tube, OR 5.60, CI 1.70–18.49) were associated with the occurrence of errors. In the hospital without full-time specialized intensive care physicians (which also lacks pharmacy-provided protocols for the preparation of parenteral drugs), more administration errors occurred, both when we included (OR 5.45, CI 3.04–9.78) and excluded wrong time errors (OR 4.22, CI 2.36–7.54). Efforts to reduce drug administration errors in the intensive care unit should be aimed at the risk factors we identified in this study. Especially, focusing on system differences between the two intensive care units (e.g., presence or absence of full-time specialized intensive care physicians, presence or absence of protocols for the preparation of all parenteral drugs) may help reduce suboptimal drug administration.

1 January 2007 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
MBMaarten J. Ten Berg
Maarten J. Ten Berg
AHAlbert Huisman
Albert Huisman
PBPatricia M.L.A. van Den Bemt
Patricia M.L.A. van Den Bemt
ASAlfred F.A.M. Schobben
Alfred F.A.M. Schobben
AEAntoine C.G. Egberts
Antoine C.G. Egberts
WSWouter van Solinge
Wouter van Solinge
Transfer of automated laboratory data collected during routine clinical care from the laboratory information system into a database format that enables linkage to other administrative (e.g., patient characteristics) or clinical (e.g., medication, diagnoses, procedures) data provides a valuable tool for clinical epidemiological research. It allows the investigation of biochemical characteristics of diseases, therapeutic effects and diagnostic and/or prognostic markers for disease with easy access and at relatively low cost. To this end, the Utrecht Patient Oriented Database (UPOD), an infrastructure of relational databases comprising data on patient characteristics, laboratory test results, medication orders, hospital discharge diagnoses and medical procedures for all patients treated at the University Medical Centre Utrecht since January 2004, was established. Current research within UPOD is focused on the innovative linkage of laboratory and medication data, which, for example, makes it possible to assess the quality of pharmacotherapy in clinical practice, to investigate interference between laboratory tests and drugs, to study the risk of adverse drug reactions, and to develop diagnostic and prognostic markers or algorithms for adverse drug reactions. Although recently established, we believe that UPOD broadens the opportunities for clinical pharmacoepidemiological research and can contribute to patient care from a laboratory perspective.

26 January 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
RLR. W. F. van Leeuwen
R. W. F. van Leeuwen
FJF. G. A. Jansman
F. G. A. Jansman
PBP. M. L. A. van Den Bemt
P. M. L. A. van Den Bemt
FMFemke De Man
Femke De Man
FPF. Piran
F. Piran
TGT. van Gelder
T. van Gelder
Drug–drug interactions (DDIs) are of major concern in oncology, since cancer patients typically take many concomitant medications. Retrospective studies have been conducted to determine the prevalence of DDIs. However, prospective studies on DDIs needing interventions in cancer patients have not yet been carried out. Therefore, a prospective study was designed to identify DDIs leading to interventions among ambulatory cancer patients receiving anticancer treatment. Patients starting with a new treatment regimen with i.v. or oral anticancer medication were asked to participate. The patients’ medication was checked for DDIs by using drug interaction software. An expert team of clinical pharmacologists evaluated the relevance of these identified DDIs. If a DDI was qualified as potentially clinically relevant, an intervention was proposed to the treating (hemato)oncologist. Several variables were studied as determinants for performing an intervention. Descriptive statistics and uni- and multivariate logistic regression analyses were carried out. In this study, 302 patients were included. A total of 603 DDIs were identified by the drug interaction software and judged by the expert team. Of all 603 DDIs, 120 DDIs were considered potentially clinically relevant. These 120 DDIs, present in a total of 81 patients, resulted in a clinical intervention already executed by the (hemato)oncologist in 39 patients (13%), while an additional intervention was proposed by a clinical pharmacologist in 42 patients (14%). The number of comorbidities and the number of ‘over-the-counter’ drugs were identified as determinants. Clinical interventions on DDIs are frequently required among patients starting with anticancer therapy. Structured screening for these potentially clinically relevant DDIs, by (hemato)oncologists in close collaborations with clinical pharmacologists, should take place before the start and during anticancer treatment. This study was registered at the Dutch Trial Registry under number NTR3760.

1 January 2004 in Drug Safety
Verified
Journal Article
Closed access
PDF file
PBPatricia M. L. A. van Den Bemt
Patricia M. L. A. van Den Bemt
RMRonald H. B. Meyboom
Ronald H. B. Meyboom
AEAntoine C. G. Egberts
Antoine C. G. Egberts